drugset / Trial / NCT05268068
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
RandomizedParallel-groupOpen-labelBasic science
Summary
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.
Timeline
- Start
- 2019-06-27
- Primary completion
- 2020-04-26
- Completion
- 2020-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.